ERBB2 and neoplasm: Conjugation of anti-HER2 antibodies to STING activators improved the targeted delivery of STING activators, increased tumor exposure, and enhanced STING-mediated antitumor immune responses while limiting systemic toxicity (Bukhalid et al. 2020).